Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

345 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical trial results of peginterferons in combination with ribavirin.
Craxi A, Licata A. Craxi A, et al. Among authors: licata a. Semin Liver Dis. 2003;23 Suppl 1:35-46. doi: 10.1055/s-2003-41633. Semin Liver Dis. 2003. PMID: 12934167 Review.
Patients with genotype 1 infection have a 42 to 51% likelihood of response to 48 weeks of therapy. Those with genotypes 2 or 3 infection will respond to 24 weeks of therapy in 78 to 82% of cases. ...A SVR after retreatment of relapsers and nonresponders with PEG-IFN …
Patients with genotype 1 infection have a 42 to 51% likelihood of response to 48 weeks of therapy. Those with genotypes 2 or 3 infect …
IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection.
Lio D, Caruso C, Di Stefano R, Colonna Romano G, Ferraro D, Scola L, Crivello A, Licata A, Valenza LM, Candore G, Craxì A, Almasio PL. Lio D, et al. Among authors: licata a. Hum Immunol. 2003 Jul;64(7):674-80. doi: 10.1016/s0198-8859(03)00080-6. Hum Immunol. 2003. PMID: 12826369
The evaluation of combined TNF-alpha and IL-10 genotypes revealed a significant increase of the "anti-inflammatory genotype" (low-TNF/high-IL-10 producers) in resolved HCV infection group compared with patients with persistent HCV infection. On the whole, our findings sugg …
The evaluation of combined TNF-alpha and IL-10 genotypes revealed a significant increase of the "anti-inflammatory genotype" (low-TNF …
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study.
Licata A, Maida M, Cabibi D, Butera G, Macaluso FS, Alessi N, Caruso C, Craxì A, Almasio PL. Licata A, et al. Dig Liver Dis. 2014 Dec;46(12):1116-20. doi: 10.1016/j.dld.2014.08.040. Epub 2014 Sep 16. Dig Liver Dis. 2014. PMID: 25224696
Drug-induced autoimmune hepatitis group had a shorter duration of drug intake, and higher values of transaminases and gamma globulins. All patients received immunosuppressive therapy with subsequent clinical remission, and five achieved a steroid-free long-term remi …
Drug-induced autoimmune hepatitis group had a shorter duration of drug intake, and higher values of transaminases and gamma globulins …
Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
Scaglione R, Argano C, Corrao S, Di Chiara T, Licata A, Licata G. Scaglione R, et al. Among authors: licata a, licata g. J Hypertens. 2005 Mar;23(3):657-64. doi: 10.1097/01.hjh.0000160225.01845.26. J Hypertens. 2005. PMID: 15716710 Clinical Trial.
After a 4-week run-in with placebo administration, a randomized double-blind, three-arm double-dummy trial was used. All the hypertensives (HT) were allocated randomly to three treatment arms (17 patients for each group) and they were single-matched for age, gender, …
After a 4-week run-in with placebo administration, a randomized double-blind, three-arm double-dummy trial was used. All the h …
Hyperferritinemia is a risk factor for steatosis in chronic liver disease.
Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A, Cammà C. Licata A, et al. World J Gastroenterol. 2009 May 7;15(17):2132-8. doi: 10.3748/wjg.15.2132. World J Gastroenterol. 2009. PMID: 19418586 Free PMC article.
CONCLUSION: In a non-obese cohort of non-alcoholic patients with chronically abnormal LFTs without HH, high serum ferritin level is a risk factor for steatosis....
CONCLUSION: In a non-obese cohort of non-alcoholic patients with chronically abnormal LFTs without HH, high serum ferritin level is …
Treatment of hepatitis C: critical appraisal of the evidence.
Cammà C, Licata A, Cabibbo G, Latteri F, Craxì A. Cammà C, et al. Among authors: licata a. Expert Opin Pharmacother. 2005 Mar;6(3):399-408. doi: 10.1517/14656566.6.3.399. Expert Opin Pharmacother. 2005. PMID: 15794731 Review.
A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during month 1 is the best treatment option. ...The overall sustained viral response rate to these regimens is 54 - 56% following a 48-week course
A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during month 1
Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma.
Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G. Giannitrapani L, et al. Among authors: licata a. World J Gastroenterol. 2013 Apr 28;19(16):2449-55. doi: 10.3748/wjg.v19.i16.2449. World J Gastroenterol. 2013. PMID: 23674845 Free PMC article. Review.
Interleukin-6 (IL-6) is a pleiotropic cytokine which is expressed in many inflammatory cells in response to different types of stimuli, regulating a number of biological processes. ...In particular, most of the studies are quite unanimous in describing a corr …
Interleukin-6 (IL-6) is a pleiotropic cytokine which is expressed in many inflammatory cells in response to different types of stimul …
Hepatitis delta infection in Italian patients: towards the end of the story?
Stroffolini T, Sagnelli E, Sagnelli C, Russello M, De Luca M, Rosina F, Cacopardo B, Brancaccio G, Furlan C, Gaeta GB, Licata A, Almasio PL; behalf of EPACRON study group. Stroffolini T, et al. Among authors: licata a. Infection. 2017 Jun;45(3):277-281. doi: 10.1007/s15010-016-0956-1. Epub 2016 Nov 5. Infection. 2017. PMID: 27817147
METHODS: A cross-sectional study involving 16 referral centres scattered all over the country in 2014. RESULTS: Out of the 513 hepatitis B surface antigen-positive subjects enrolled, 61 (11.9%) were anti-delta positive, with a sex ratio (M/F) of 2.05. ...CONCLUSIONS …
METHODS: A cross-sectional study involving 16 referral centres scattered all over the country in 2014. RESULTS: Out of the 513 hepati …
When and how to treat acute hepatitis C?
Licata A, Di Bona D, Schepis F, Shahied L, Craxí A, Cammà C. Licata A, et al. J Hepatol. 2003 Dec;39(6):1056-62. doi: 10.1016/s0168-8278(03)00461-6. J Hepatol. 2003. PMID: 14642626
BACKGROUND: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large controlled trials. ...A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during the 1 …
BACKGROUND: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large controlled trials. . …
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV). Calvaruso V, et al. Among authors: licata a. Gastroenterology. 2018 Aug;155(2):411-421.e4. doi: 10.1053/j.gastro.2018.04.008. Epub 2018 Apr 12. Gastroenterology. 2018. PMID: 29655836

RESULTS: A sustained virologic response (SVR) was achieved by 2,140 patients (total = 95.2%; 95.9% with Child Pugh class A and 88.3% with Child Pugh class B; P < .001). ...A larger proportion of patients with an SVR had a single HCC lesion (78% vs 5

RESULTS: A sustained virologic response (SVR) was achieved by 2,140 patients (total = 95.2%; 95.9% with Child Pugh class A and …
345 results
Jump to page
Feedback